You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Rexahn to raise $10M in registered direct offering
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
Rexahn Pharmaceuticals Inc. announced a $10 million registered direct offering with institutional investors to advance three anti-cancer compounds: RX-3117, Supinoxin and Archexin.
The company will issue 3,030,000 shares priced at $3.30 apiece, complete with warrants to buy up to an additional 1,520,000 shares for $4 per share within five years from the date of issue.
Rodman & Renshaw is the exclusive placement agent for the offering, which is expected to close by June 12.